Monthly Archives: September 2012

Affordable Care Act: Where's the Sunshine?

By Guest Blogger | Published: September 7, 2012
Where’s the Sunshine? The Senate Special Committee on Aging is holding a Roundtable discussion on Wed. Sept. 12, 2012 in hopes of spurring action to implement the “Sunshine” provisions of the Affordable Care Act (ACA). Policies for collecting and submitting information on pharma payments to doctors were supposed to be issued by last September (2011), so [...]
Posted in Guest Blog, Op-Ed, Regulatory, healthcare | Tagged , , , , | Leave a comment

Measuring Responsibility in Big Pharma

By Guest Blogger | Published: September 7, 2012
Measuring Responsibility in Big Pharma If you can’t measure it, the saying goes, it doesn’t count.  But what if you’re measuring the wrong things? The Access to Medicines Index (www.accesstomedicineindex.org) is an attempt to measure and compare the corporate social responsibility of both innovator (20) and generics (7) companies based on a number of different (and often [...]
Posted in Corporate Responsibility, Guest Blog, healthcare | Tagged , , , , , | Leave a comment

Advancing Pharma's Social Media Listening Analytics

By Ben Comer | Published: September 6, 2012
Big Pharma’s tin ear for social, user-generated content online is softening despite regulatory anxiety. In the quest to better understand what patients and doctors need, pharma – thanks in part to a bevy of third-party service providers – is beginning to recognize and incorporate insights from social media into their development and commercialization programs, according [...]
Posted in Advertising, Agency Insight, E-Media, Marketing, Regulatory, Sales, Strategy, Technology, social media | Tagged , , , | 5 Comments

FDA, AdvaMed Seeking Clarity on Med Device Pre-Market Approvals

By Guest Blogger | Published: September 5, 2012
by Elizabeth Hollis The FDA and the Advanced Medical Technology Association (AdvaMed) gave cardiovascular device manufacturers plenty to think about over the holiday weekend with information presented at an Aug. 28 workshop. The two bodies came together to explain requirements for 30-day notices and annual change reports for Pre-Market Approvals (PMAs), an important gateway to [...]
Posted in FDA, Guest Blog, IP, Legal, Manufacturing, Market Access, Meetings, Regulatory, Safety, Strategy, Technology | Tagged , | 1 Comment